Allogeneic HSCT is a mainstay for patients with different hematological malignancies, but it requires immunosuppressive strategies before and after HSCT. However, approximately half (50%) of the patients receiving allogeneic hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-matched sibling experience acute GVHD. These rates are higher in unmatched donors. In the United States, around 25,000 hematopoietic stem cell transplants (HSCTs) are performed yearly, with ~40% being allogenic.
The treatment of GvHD involves using immunosuppressive drugs such as corticosteroids, calcineurin inhibitors, and monoclonal antibodies. Off-label therap...
